

# Prevalence of Histological Reflux Oesophagitis in H. Pylon Positive Patients: Effect of density of H. Pylori and Activity of Inflammation

Z. Abbas, R. Fareed, M.N. Baig, T.N. Khan, M.A. Shah ( Department of Medicine. Jinnah Postgraduate Medical Centre. Karachi. )

## Abstract

**Objective:** Recently there has been a great interest in the role of *Helicobacter pylori* in gastroesophageal reflux disease. Many studies do not show any significant difference in the overall prevalence of *H. pylori* in patients with endoscopic oesophagitis and controls. In this prospective study we assessed the influence of *H. pylori* density and activity of inflammation in different parts of stomach on histological oesophagitis.

**Methods:** One Hundred and forty consecutive patients undergoing endoscopy for dyspepsia and heartburn were evaluated. Three biopsies were taken from antrum and two each from corpus, cardia and lower oesophagus. Urease test (CLO test) was performed. Density and activity of infection was assessed in a semi-quantitative way.

**Results:** One Hundred and Fourteen (81%) patients from the 140 endoscoped, were positive for *H. pylori* and had *H. pylori* positive antral gastritis. Of these 114 cases, *H. pylori* were detectable in 104 (91%) of biopsies taken from corpus and 96 (84%) of biopsies from cardia. There was a strong correlation of density of *H. pylori* (0-3) in antrum with body and of body with cardia by Spearman correlation tests ( $p=0.000$ ). But *H. pylori* were more dense in antrum as compared to corpus and in corpus as compared to cardia ( $p=0.0000$  and  $0.0003$  respectively by Wilcoxon's rank test). Neutrophil activity and degree of mononuclear infiltrate were also greater in antrum as compared to corpus ( $p=0.000$  and  $0.059$ ). The activity and degree of inflammation was not significantly different in corpus-cardia pair. Out of 114 *H. pylori* positive patients, 75 had histological oesophagitis ( $p=0.855$ ). After excluding cases of hiatal hernia (HH) and gaping lower oesophageal sphincter (LOS), number of *H. pylori* positive patients decreased to 73, out of these 50 had histological oesophagitis ( $p=0.103$ ). In all *H. pylori* positive patients with histological oesophagitis, *H. pylori* density (1-3) in antrum correlated with severity of oesophagitis ( $P=0.011$ ). Neutrophil activity in antrum and corpus also correlated with the severity of histological oesophagitis ( $P=0.024$  and  $0.035$  respectively). Correlation further improved after excluding cases of HH and gaping LOS ( $P=0.002$  for *H. pylori* density and  $0.026$  and  $0.004$  for activity in antrum and corpus). No correlation could be found of density and activity of infection in cardia with histological oesophagitis.

**Conclusion:** Our *H. pylori* positive patients had more dense and severe infection in antrum. Those who had histological oesophagitis in addition showed a positive correlation of the density of *H. pylori* in antrum and neutrophil activity in antrum and corpus with the severity of histological oesophagitis (JPMA 51:36; 2001).

## Introduction

*Helicobacter pylori* is considered to be a pathogenic factor in gastritis, peptic ulcer, gastric cancer and MALT lymphoma<sup>1,2</sup>. Recently much interest has been generated to ascertain any relationship of *H. pylori* with gastroesophageal reflux disease (GORD). *H. pylori* is known to increase gastrin release and acid output<sup>3-5</sup>. It may also reflexly affect lower oesophageal sphincter and delay gastric emptying<sup>6-10</sup>.

All these factors are known to play significant role in the pathogenesis of GORD<sup>11-15</sup>. There are studies to show increased prevalence of reflux oesophagitis in the patients with duodenal ulcer<sup>16-18</sup>. Contrary to this, recent work From the West shows that eradication of *H. pylori* from stomach may end up in GORD<sup>19,20</sup> and decline in the prevalence of *H. pylori* has been accompanied by an increase in GORD associated complications e.g. Barretts adenocarcinoma of distal oesophagus.

In low socio-economic strata of Karachi, majority of patients undergoing endoscopy for dyspepsia are positive for *H. pylori*. Many patients of dyspepsia have an overlap of both ulcer like and reflux like symptoms<sup>21</sup>. Studies have shed light on the role of acid reflux as well as of *H. pylori* in causing dyspepsia<sup>22,23</sup>. How does *H. pylori* influence the reflux disease in our patients is difficult to ascertain due to low number of *H. pylori* negative patients. In order to address further the conflicting *H. pylori* -GORD interaction, we did a prospective study. Purpose of this study was to determine the effects of colonization of antrum, corpus and cardia by *H. pylori* on reflux oesophagitis considering the following aspects (1) presence or absence of *H. pylori* (2) density of *H. pylori* colonization (3) severity of neutrophil activity and (4) degree of chronic inflammation.

## **Methods**

### **Patient selection**

Patients of dyspepsia and heartburn undergoing upper gastrointestinal endoscopy were considered for the study after obtaining informed consent to the study protocol. Background data was collected on age, sex, social class, symptoms and medication. Only patients with upper gastrointestinal symptoms for at least one month were included. Exclusions were recent intake of proton pump inhibitors (PPIs) or non-steroidal anti-inflammatory drugs (NSAIDs) within last two weeks or antibiotics in the last four weeks. Patients found to have varices or malignancy on endoscopy were also excluded from analysis. Our patients belonged to the low socioeconomic class.

### **Endoscopy**

Endoscopy was performed with Olympus videoscope (GIF130) or fibro-optic scope (GIF2T20, GIFXQ20). Biopsy specimens were obtained with standard biopsy forceps (Olympus FB-24U). Biopsies were taken: three from antrum and two each from the body of stomach, cardia and distal oesophagus. Biopsies from body of stomach were obtained from greater curvature and one each from anterior and posterior wall. Gastric cardia biopsies were obtained with the endoscopy in the retroflexed position about 5mm from squamocolumnar junction. In the case of hiatal hernia biopsies were obtained from hernia sac from the proximal edge of gastric folds below 'Z' line. Oesophageal biopsies were taken about 3cm above the squamocolumnar junction. Endoscopic grading of oesophagitis was performed by using the criteria of Hetzel et al 24 Grade 1, erythema or hyperaemia of oesophageal mucosa with no macroscopic erosions; grade 2, superficial ulceration or erosions involving <10% of the last 5cm of oesophageal squamous mucosal surface; grade 3, superficial ulceration or erosions involving 10-50% of the last 5cm of oesophageal squamous mucosal surface; and grade 4, deep ulcers anywhere in the oesophagus or confluent erosions involving >50% of the last 5cm of oesophageal squamous mucosal surface.

### **Histology**

An antral biopsy was used for urease test while rest of the biopsy specimens were stained with haematoxylin and eosin and Giemsa stains. Two experienced pathologists blind to the endoscopic findings assessed the specimens. Oesophageal specimens were evaluated for the presence or absence of histological oesophagitis using a four point visual analogue scale (0-3 scale) (Table 1). Grading of gastric specimens was done based on Sydney System modified by Dixon et al<sup>25</sup>. Following features were assessed (1) presence or absence of *H. pylori* (2) density of *H. pylori* colonization (3) severity of neutrophil activity and (4) degree of colonic inflammation (Table 1).

**Table 1. Semiquantitative Evaluation of Oesophageal And Gastric Biopsies.**

---

**A. Oesophagitis**

- 0 = Normal papillae and basal layers; no polymorphonuclear cells (PNCs).
- 1 = Increase in papillae length and basal layer thickness, no PNCs.
- 2 = Increase in papillae length and basal layer thickness with PNCs+1.
- 3 = Marked increase in papillae length and basal layer thickness and numerous PNCs

**B. H. pylori density**

- 0 = No organism identified.
- 1 = Rare organisms present.
- 2 = Organisms present in many but not all high dry fields (40x).
- 3 = Plentiful bacteria in all fields.

**C. Neutrophil activity**

- 0 = No extravascular neutrophils.
- 1 = Scattered lamina propria extravascular neutrophils.
- 2 = Neutrophils infiltrating a minority of gastric pits.
- 3 = Neutrophils infiltrating majority of gastric pits/infiltrate within foveolar lumen

**D. Chronic inflammation.**

- 0 = Occasional lymphocytes and plasma cells (up to 5).
  - 1 = Mild increase in mononuclear cells (MNCs) (6-10/HPF).
  - 2 = Diffuse increase in MNCs (11-20/HPF).
  - 3 = Diffuse dense increase in MNCs (>20/HPF).
- 

Patient was considered H. pylori positive if histological examination of any one of the multiple gastric biopsy specimens revealed H. pylori or the rapid urease test was positive.

**Statistics**

Calculations were performed using SPSS package. Significance was considered at 5% probability level.

Effects of presence or absence of *H. pylori* on presence or absence of oesophagitis were tested with chi square with Yate's correction. Spearman correlation coefficients were calculated for histological parameters of different biopsy sites in order to assess the correlation of gastritis with the severity of histological oesophagitis. Wilcoxon matched-pair signed-ranks test was used for comparison of paired samples to show differences in *H. pylori* gastritis in antrum, corpus and cardia.

## **Results**

During the study period, 140 consecutive patients who met the selection criteria were evaluated. Their demographic characteristics are given in Table 2.

**Table 2. Demographic Characteristics of the study patients.**

Total number of patients	140
Sex	
Male	85
Female	55
Age	
Mean $\pm$ S.D (yr.)	35.5 $\pm$ 13.5
Median (range)	32(15-85)
Endoscopic findings: n (%)	
Hiatal hernia	31 (22)
Gapping lower oesophageal Sphincter	25 (18)
Clinical oesophagitis	49 (35)
Antral erythema (alone)	18(13)
Pangastric erythema	50 (36)
Duodenal disease	17 (12)
Histological oesophagitis*	91 (65%)
Positive H. pylori**	
Antrum	114 (81)
Corpus	104 (74)
Cardia	96 (69)

\*p value for Spearman correlation for severity of clinical and histological oesophagitis = 0.009

\*\*p values for Spearman correlation for H. pylori presence and density in different sites (antrum-corpus, corpus-cardia, antrum-cardia = 0.000 for each pair)

One Hundred and fourteen cases were positive for H. pylori. H. pylori positive antral gastritis was present in all 114 patients. Bacteria were detectable in 104 (91%) of corpus biopsies and 96 (84%) of biopsies taken from cardia. Though there was a strong correlation of density of H. pylori (0-3) in antrum with body and of body with cardia by Spearman correlation test, Wilcoxon's signed rank test

for paired samples showed significant differences in the density as we proceeded to the cardia (antrum > body,  $p=0.0000$ , body > cardia,  $p=0.0003$ ). Neutrophil activity in antrum was greater than corpus ( $p=0.0000$ ). A trend of decrease in the degree of mononuclear infiltrate was also noticed here (antrum > corpus,  $p=0.0592$ ). The activity and degree of inflammation was not significantly different in corpus - cardia pair ( $p=0.863$  and  $0.664$  respectively).

H. pylori were present in 114 patients. Out of these 75 had histological oesophagitis. No apparent effects of presence of H. pylori in the stomach on presence or absence of histological oesophagitis could be found by using chi square with Yate's correction ( $p=0.855$ ). As hiatal hernia and gapping lower oesophageal sphincter also contribute to the reflux oesophagitis, the analysis was done again after excluding above cases. Total H. pylori positive cases were 73, out of these 50 had evidence of histological oesophagitis ( $p=0.103$ ). In 11. pylori positive cases with histological oesophagitis, the influence of gastritis of different parts of stomach on severity of histological oesophagitis was evaluated using Spearman correlation test. In these cases, H. pylori density in the antrum and activity of inflammation in antrum and corpus correlate with the severity of oesophagitis with significant p values (Table 3).

**Table 3. H. Pylori positive patients with positive histological esophagitis: correlation of severity of esophagitis with different parameters.**

	All H. pylori positive cases (n=75 )		H. pylori positive without hiatal hernia or gapping LOS (n=50)	
	Correlation coefficient	P value	Correlation coefficient	P value
<b>H. pylori density</b>				
Antrum	0.293	0.011*	0.429	0.002*
Corpus	0.114	0.330	0.217	0.130
Cardia	-0.001	0.994	0.073	0.616
<b>Neutrophil activity</b>				
Antrum	0.26	0.024*	0.315	0.026*
Corpus	0.244	0.035*	0.405	0.004*
Cardia	-0.035	0.961	0.062	0.668
<b>Degree of mono-nuclear infiltration</b>				
Antrum	-0.071	0.545	-0.204	0.156
Corpus	-0.117	0.319	-0.139	0.335
Cardia	-0.057	0.627	-0.144	0.317

\*Statistically significant values.

### Discussion

Infection with H. pylori is common and may coexist with another process e.g. GORD. H. pylori is not present in the squamous epithelium of distal oesophagus. Will the presence of H. pylori in the stomach and cardia influence GORD? Recently there has been a great interest in the role of H. pylori in reflux disease. Most of the studies do not show any significant difference in the overall prevalence of H. pylori in patients with GORD and control population<sup>26-28</sup>. Many of these studies define 'reflux group'

based on symptoms and compare it with a group of 'controls'; a heterogeneous group of patients undergoing endoscopy for reasons other than reflux.

In our study instead of reporting the prevalence of *H. pylori* in patients with GORD, we have assessed the prevalence of oesophagitis in patients with gastritis independent of any symptom-based group. We examined the potential influences of presence or absence of *H. pylori* infection, effect of its density, activity and degree of inflammation and distribution of *H. pylori* in different parts of stomach on reflux oesophagitis. Instead of focusing on endoscopic oesophagitis, we have compared histological oesophagitis with histological changes in stomach to pick up microscopic influences of infection independent of confounding variables of symptoms. We share the feelings of Wilkinson, et al, that endoscopy alone, without histology, has poor sensitivity and specificity for diagnosing diffuse mucosal diseases of oesophagus and stomach<sup>29</sup>.

Factors involved in the pathogenesis of GORD include lower oesophageal sphincter dysfunction with inappropriate LOS relaxations<sup>30,31</sup>, disturbed or delayed gastric emptying<sup>32,33</sup>, disturbed or delayed gastric accommodation response to swallowing<sup>34</sup>, impaired oesophageal clearance of gastric contents<sup>35</sup> and hypersecretion of gastric acid<sup>36</sup>.

High incidence of oesophagitis has been reported in patients with duodenal ulcer disease<sup>16-18</sup>. The reason is not clear though increase in basal acid output, hypergastrinemia and altered gastric emptying may be the contributing factors. In duodenal ulcer patients *H. pylori* causes increase in basal acid output and increase in meal stimulated gastrin release<sup>37,38</sup>, reduced accommodation (diastolic dysfunction) of stomach to a meal and delayed gastric emptying<sup>6-10</sup>. All these factors might be contributing.

Theoretically *H. pylori* could contribute to the development of reflux disease even in patients without duodenal ulcer by increasing acid secretion with predominant antral gastritis and impairing gastric emptying. Other possible mechanisms could be production of cytotoxins harmful to oesophageal mucosa and by reflex impairment of function of lower oesophageal sphincter by inflammation of fundus<sup>49</sup> as studies have shown a neural mechanism controlling LOS with afferent limb of the reflex arc originating in fundus<sup>40,41</sup>. However recent epidemiological studies from the West have shown a decline in peptic ulcer and *H. pylori* paralleling with increasing incidence of GORD, Barrett's and adenocarcinoma of oesophagus<sup>42,43</sup>. It has been suggested that *H. pylori* may have a potentially protective effect against GORD. The corpus inflammation induced by Cag A positive strains may lead to atrophic gastritis with loss of gastric acidity<sup>44</sup>. Ammonia generated by *H. pylori* may also be responsible for neutralizing the acid. So the eradication of *H. pylori* may reverse this effect, leading to an increase in the frequency of GORD.

Our study does not show any influence of presence or absence of *H. pylori* on presence or absence of oesophagitis; a conclusion shared by many other workers. Most of our patients were *H. pylori* positive and we do not have an adequate size comparison group of *H. pylori* negative patients. But an interesting correlation was seen in our *H. pylori* positive patients with histological oesophagitis. In these cases, density of *H. pylori* infection in antrum and neutrophil activity in antrum and corpus positively correlated with the severity of histological oesophagitis. Our relatively young patients had predominant antral gastritis, probably still having high acid output. Few other workers have shown a positive association of *H. pylori* with oesophagitis as well<sup>45-46</sup>.

Previous studies done in *H. pylori* positive patients have shown increased basal, meal stimulated and gastrin releasing peptide (GRP) stimulated gastrin concentrations<sup>47-49</sup> resulting in increased basal acid and GRP stimulated acid secretion<sup>50,37</sup>. Eradication of *H. pylori* results in normalization of acid response<sup>48-50</sup>. Eradication of *H. pylori* also restores the cholecystinin (CCK) stimulated release of somatostatin from D cells<sup>51</sup>. It has been suggested that inflammatory mediators and cytokines, TNF $\alpha$  and IL 13 are responsible for the release of gastrin and attenuation of effect of CCK on D cells<sup>52</sup>. So

active inflammation and release of these cytokines mediators are responsible for increase in acid output. A subgroup of patients does exhibit lowering of gastric acid secretion associated with corpus predominant gastritis with atrophic changes<sup>53</sup>. Our patients had pangastritis but the group with histological oesophagitis still had very active antral inflammation probably pouring out higher acid. Recent studies in which biopsies were taken from different sites have shown that even the patients of duodenal ulcer have pangastritis with *H. pylori* spreading up to the cardia<sup>54,55,27</sup>. So when the infection is present in antrum, it is present usually in the rest of stomach and activity of inflammation seems to be more important predictor of increased acid output than mere distribution.

Recent belief of negative association of *H. pylori* infection with GORD has been developed from some reports that eradication of *H. pylori* may be followed by development of GORD<sup>19,20,56</sup>. In one study reflux oesophagitis occurred in 25.8% of patients with duodenal ulcer after successful eradication therapy compared to 12.9% patients who remained positive for *H. pylori* during the follow up period of 3 years<sup>19</sup>. Other studies do not favour it. In one short-term study of 244 patients with peptic ulcer disease, symptoms of GORD were present in 20% of patients. Symptoms remained the same in 83% of patients, improved in 11% and worsened in only 6% of individuals who underwent successful eradication therapy<sup>57</sup>. In another study during a 6 month follow up of 242 patients with duodenal ulcer, new symptoms of heartburn developed in 20%, irrespective of their *H. pylori* status<sup>58</sup>, may be that many patients of duodenal ulcer have co-existing GORD<sup>59</sup> and symptoms of reflux are masked by the initial diagnosis as these patients are on antacids and anti-secretory drugs. Withdrawal of these drugs and weight gain after cure of infection would account for recurrence of symptoms.

In a study done by Pieramico et al<sup>60</sup>, overall prevalence of *H. pylori* in patients presenting with GORD was 48.7%. Patients with oesophagitis had a statistically greater prevalence of infection (56.9%) compared with no oesophagitis. This was comparable with a prevalence of 54.2% in patients with non-ulcer dyspepsia.

In our study, though the density of *H. pylori* in cardia correlated with the density in the corpus and antrum by Spearman correlation, Wilcoxon's signed rank test for paired samples showed a significant reduction in the absolute density as we proceeded to the cardia (antrum body > cardia). Neutrophil activity and mononuclear infiltrates were greater in antrum as compared to corpus and there was no significant difference in corpus - cardia pair. Both antral and cardiac mucosae mainly consist of surface mucus cells with low acidity, one may expect a similar density of *H. pylori* colonization and inflammatory activity in both areas. Why the density of *H. pylori* in cardia is low is not clear. Similar results have been shown by Hackeisberger et al<sup>54</sup>. Higher inflammatory activity in the antrum as compared to rest of stomach indirectly reflects that our patients were producing more, thereby influencing the severity of GORD. No correlation of density of *H. pylori* colonization in cardia or inflammatory activity of cardia with severity of histological oesophagitis could be found. Rather activity of cardiac gastritis was correlated with that of the corpus.

If we admit that theoretically *H. pylori* could contribute to the development of pathophysiological abnormalities which would make GORD more likely, then it seems logical that dense and active *H. pylori* infection in the antrum would make the histological oesophagitis worse mainly through altered gastric acid production. Further work is needed based on pH studies and biopsies before and after *H. pylori* eradication.

## References

1. Marshall BJ. *Helicobacter pylori*. Am J Gastroenterol, 1994; 89: S116-28.
2. Forbes GM. *Helicobacter pylori*. Current issues and new directions Gastroenterol Hepatol 1997; 12: 419-24.

3. Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: Effects of eradication of *Helicobacter pylori*. *Gut*, 1993;34;888-92.
4. Wagner S, Gladziwa v, Haruma K. et al. Effects of *Helicobacter pylori* infection on 24 hour intragastric activity in patients with gastritis and duodenal ulcer. *GUT*.1992; 33 1024-8.
5. Smith JTL, Pounder RE, Nwokolo CU, et al. inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with *Helicobacter pylori* infection. *GUR*, 1 990; 31: 522-5.
6. Fock KM, Khoo TK, Chia KS, et al. *Helicobacter pylori* infection and gastric emptying of indigestible solids in patients with dysmotility like dyspepsia. *Scand J. gastroenterol.*, 1997;32 676-80.
7. Okumura I, Shoji E, Takahashi N, et al. Delayed gastric emptying by *Helicobacter pylori* lipopolysaccharide in conscious rats *Dig. Dis. Sci.*, 1998; 43: 90-4.
8. Murakami K, Fujioka T, Shiota K. et al. Influence of *Helicobacter pylori* infection and the effects of its eradication on gastric emptying in nonulcerative dyspepsia. *Eur. J. Gastroenterol. Hepatol.*, 1995; 7 (Suppl 1): 593-7
9. Moore Sc, Malagelada JR, Shorter RG, et al. Interrelationships among gastric mucosal morphology, secretion and motility in peptic ulcer disease. *Dig. Dis. Sci.* . 1986; 31: 673-84.
10. Iestoni PA, Bagnolo F, Masci Let at. Different interdigestive antroduodenal motility patterns in chronic antral gastritis with and without *Helicobacter pylori* infection. *Dig. Dis. Sci.*. 1993; 38: 2255-61.
11. Hirschowitz BI, A critical analysis, with appropriate control of gastric acid and pepsin secretion in clinical esophagitis *Gastroenterology*, 1991; 101: 1149-58.
2. Collen MJ, Johnson DA, Sheridan Mi. Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease: Correlation with ranitidine therapy. *Dig. Dis. Sci.*, 1994; 39 4 10-17.
13. Scarpignato C. Gastric emptying and gastroesophageal reflux disease and other functional esophageal disorders: functional evaluation in esophageal disease. *Front. gastrointestinal Res*, 1994; 22: 223-59.
14. Richter JE. Delayed gastric emptying in reflux patients: to be or not to be? *Aiii. J. gastroentrol.*, 1997; 92: 1077-8.
15. Cadot G, Bruhat A, Riguad D, et al. Multivariate analysis of pathophysiological features in reflux oesophagitis *Gui*, 1997; 40 167-74.
16. Flook D, Stoddard DJ. Gastro-oesophageal reflux and oesophagitis before and after vagotomy for duodenal ulcer. *Br. J. Surg.*, 1985; 72: 804-7.
17. Earlam RJ, Amerigo J, Kakavoulis T, et al. Histological appearances of oesophagus, antrum and duodenum and their correlation with symptoms in a patient with duodenal ulcer. *Gut*, 1985: 26: 95-100.
18. De Moraes-Filho JPP, Zaterka S, Pinotti W, et al. Esophagitis and duodenal ulcer. *Digestion.*, 1974; 11. 338-46.
19. Labenz J, Blum AL, Bavedorffer E, et al. Curing *Helicobacter pylori* infection in patients with duodenal ulcer may provoke reflux esophagitis. *Gastroenterology*, 1997; 112: 1442-7.
20. Xia HH, Talley NJ. *Helicobacter* infection reflux esophagitis and atrophic gastritis: an unexplored triangle. *Am. J. Gastroenterol.*, 1998; 93: 394-400.
21. Talley Ni. Dyspepsia and heartburn: a clinical challenge. *Aliment pharmacol. Ther.*, 1997: 11(Suppl.2): 1-8.
22. Small PK, Loudon MA, Waldron B, et al. Importance of reflux symptoms in functional dyspepsia. *Gut*, 1995; 36: 1 89-92.
23. Unge, P. Assessment and significance of *Helicobacter pylori* infection. *Aliment Pharmacol. Ther.*, 1997: 11 (suppl-2): 33-9.
24. Hetzel DJ, Dent J, Read WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. *Gastroenterology*, 1988; 95: 903-12.
25. Dixon MF, Genta RM, Yardley J, et al. Classification and grading of gastritis: the updated Sydney

system. *Am. J. Surg. Pathol.*, 1996; 20: 1161-81.

26. Lee JM, O'Morian CA. Different management for *Helicobacter pylori* positive and negative patients with gastro-oesophageal reflux disease. *Gut*, 1998; 43 (Suppl- 1): S14-20.

27. Newton M, Bryan R, Bumhan WR, et al. Evaluation of *Helicobacter pylori* in reflux oesophagitis and Barrett's oesophagus. *Gut*, 1997; 40: 9-13.

28. Werdmuller IJFM, Loffeld RJLF. *Helicobacter pylori* infection has no role in the pathogenesis of reflux esophagitis. *Dig. Dis. Sci.*, 1997; 42: 103-5.

29. Wilkinson, SP. The limits of endoscopy in the diagnosis of oesophagitis, gastritis and duodenitis. *Aliment. Pharmacol. Ther.*, 1997, 11 (suppl. 2): 13-7.

30. Dodds WJ, Dent J, Hogan WJ. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. *N Engl. J. Med.*, 1982; 307: 1547-52.

31. Dent J, Holloway RH, Jooji J, et al. Mechanisms of lower esophageal sphincter incompetence in symptomatic patients with gastroesophageal reflux. *Gut*, 1988; 29: 1020-8.

32. McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastroesophageal reflux. *Gastroenterology*, 1981; 80: 285-91.

33. Maddern GJ, Chatterton BE, Collins P, et al. Solid and liquid gastric emptying in patients with gastro oesophageal reflux. *Br. J. Surg.*, 1985; 72: 344-7.

34. Hartley MN, Walker SI, Mackie CR. Abnormal gastric adaptive relaxation in patients with gastroesophageal reflux. *GUT*, 1990; 31: 500-3.

35. Stancin C, Bannet JR. Oesophageal acid clearing: One factor in the production of reflux esophagitis. *Gut*, 1974; 15: 852-7.

36. Collen MI, Lewis JI, Benjamin SB. Gastric acid secretion in refractory gastroesophageal reflux disease. *Gastroenterology*, 1990, 98: 654-61.

37. Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of *H. pylori*. *Gut*, 1993; 34: 888-92.

38. Graham DY, Opekun A, Less GM, et al. *Helicobacter Pylori*-associated exaggerated gastrin release in duodenal ulcer patients. The effect of bombesin infusion and urea ingestion. *Gastroenterology*, 1991; 100: 1571-5.

39. Vicari J, Falk GW, Richter JE. *Helicobacter pylori* and acid peptic disorders of the oesophagus: is it conceivable? *Am. J. Gastroenterol.* 1997; 92: 1097-102.

40. Holloway RH, Ilongo M, Berger K, et al. Gastric distension: A mechanism for post-prandial gastroesophageal reflux. *Gastroenterology* 1985; 89: 779-84.

41. Wyman JB, Dent J, Heddl R, et al. Control of belching by the lower oesophageal sphincter. *Gut*, 1990; 31: 639-46.

42. El-Serag HB, Sonnenberg A. Opposing time trends of peptic and reflux disease. *Gastroenterology*, 1997; 112: A113.

43. Pera M, Cameron AJ, Trastek VF, et al., Increasing incidence of adenocarcinoma of the oesophagus and esophagogastric Junction. *Gastroenterology*, 1993; 104: 510-3.

44. Vicari JJ, Peek KM, Falk GW, et al. The seroprevalence of cag A-positive *Helicobacter pylori* strains in the spectrum of gastroesophageal reflux disease. *Gastroenterology*, 1998; 115: 50-7.

45. Sekiguchi T, Shirota T, Horikoshi T, et al. *Helicobacter pylori* infection and severity of reflux esophagitis. *Gastroenterology*, 1996; 110: A755-56.

46. Cargill G, Atan P, Tudor D, et al. Association of *Helicobacter pylori* and reflux esophagitis in symptomatic children. *Gastroenterology*, 1994; 106: A59-A61.

47. McColl KEL, Fullerton JM, Cliftajulla R, et al. Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of *Helicobacter pylori* in duodenal ulcer subjects. *Scand. J. Gastroenterol.*, 1991; 26: 339-46.

48. El-Omar E, Penman ID, Ardill JES, et al. *Helicobacter pylori* infection and abnormalities of acid secretion in patients with duodenal ulcer disease. *Gastroenterology*, 1995; 109: 681-91.

- 49.El-Omen E, Penman I, Dorrian CA, et al. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. *Gut*, 1993; 34: 1060-5.
- 50.Harris AW, Gummett PA, Misiewicz Ji, et al Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin *Gut*, 1996; 37: 663-8.
- 51.Buchan AM, Melolie RM, Kwok YN, et al. Effect of cholecystokinin and secretin on somatostatin release from cultured antral cells, *Gastroenterology*, 1993; 104: 1414
- 52.Weigert N, Schaffer K, Schusdziarna V. Gastrin secretion from primary cultures of rabbit antral G cells: Stimulation by inflammatory cytokines. *Gastroenterology*, 1996; 110: 147-54.
- 53.El-Omen EM, Dien K, El-Nulumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. *Gastroenterology*. 1997; 113: 15-24.
- 54.Hackelsberger A, Giinther T, Schultze V. et al. Prevalence and pattern of Helicobacter pylori gastritis in gastric cardia. *Am. J. Gastroenterol.*, 1997; 92 2220-4.
- 55.Genta RM, Huberman RM, Graham DY. The gastric cardia in Helicobacter pylori infection. *Hum. Pathol.*, 1994; 25: 915-9.
- 56.Labenz J, Tillenburg B, Peitz U. et al. Long-term consequences of Helicobacter pylori eradication: Clinical aspects. *Scand J. Gastroenterol*, 1996;31 (suppl 215): 111-5.
- 57.Oconnor HJ, McGee C, Mehana N, et al. Prevalence of gastro-oesophageal reflux disease in H. pylori positive peptic ulcer disease and the short-term effects of eradication therapy. *Gut*, 1997;41 (suppl 1): A54-A56.
- 58.Vakil N, McSorley D, Hahn B, et al. Reflux symptoms after H pylori treatment in duodenal ulcer. *Gut*, 1997; 41(suppl 1): A128.
- 59.Boyd EJS. The prevalence of esophagitis in patients with duodenal ulcer on ulcer like dyspepsia. *Am J Gastroenterol.*, 1996; 91: 1539-43.
- 60.Pieramico O, Zanetti MV. Role of H. pylori infection in gastroesophageal reflux disease. *Gut*, 1997; 41 (suppl 1): A24-A-25.